November 22, 2016 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2016 Read more
October 18, 2016 Non Regulatory Results from InDex Pharmaceuticals’ COLLECT study well received at UEGW Read more
October 10, 2016 Non Regulatory InDex Pharmaceuticals presents results from the COLLECT study at the United European Gastroenterology Week 2016 Read more
September 30, 2016 Non Regulatory InDex Pharmaceuticals announces the outcome of its initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
September 26, 2016 Non Regulatory InDex Pharmaceuticals ends the subscription period for the initial public offering in connection with listing on Nasdaq First North Tuesday, September 27 Read more
September 14, 2016 Non Regulatory InDex Pharmaceuticals initiates the subscription period for the initial public offering in connection with planned listing on Nasdaq First North Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals publishes prospectus regarding initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals conducts initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
August 25, 2016 Non Regulatory InDex Pharmaceuticals Holding AB – Interim Report 27 June – 30 June 2016 Read more
August 15, 2016 Non Regulatory InDex Pharmaceuticals AB – Interim Report January – June 2016 Read more
May 23, 2016 Non Regulatory InDex Pharmaceuticals receives grant from Sweden´s innovation agency Vinnova for pre-clinical development of DIMS compounds in inflammation Read more
March 7, 2016 Non Regulatory InDex Pharmaceuticals Receives FDA Clearance of IND for Cobitolimod (Kappaproct®) Phase IIb Trial Read more
February 10, 2016 Non Regulatory InDex Pharmaceuticals receives approval of the International Nonproprietary Name (INN) cobitolimod for their lead drug candidate Kappaproct® Read more